{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:52:27Z","timestamp":1786589547153,"version":"build-2736575974"},"reference-count":179,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NW26-01-00189"],"award-info":[{"award-number":["NW26-01-00189"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Univerzita Palack\u00e9ho v Olomouci","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Inflammatory bowel diseases (IBD), including Crohn\u2019s disease and ulcerative colitis, are chronic immune-mediated diseases that are increasingly recognized as systemic diseases with significant cardiovascular consequences. Growing epidemiological evidence suggests that patients with IBD face an increased risk of atherosclerotic cardiovascular disease (ASCVD) that cannot be fully explained by traditional cardiovascular risk factors. This excess risk is most pronounced in younger patients and during periods of active intestinal inflammation. This review summarizes current knowledge on common pathogenic mechanisms linking IBD and ASCVD. Chronic systemic inflammation plays a central role, promoting endothelial dysfunction, hypercoagulability, immune cell activation, and accelerated atherogenesis. Other factors include intestinal barrier disruption with microbial translocation, dysbiosis of the gut microbiome, dysfunctional visceral adipose tissue, and adverse metabolic effects of some IBD therapies. Particular emphasis is placed on lipid abnormalities observed in IBD, including the \u201clipid paradox\u201d, a phenomenon in which reduced circulating lipid levels paradoxically coexist with increased cardiovascular risk due to inflammation-mediated changes in lipid metabolism leading to lipoprotein dysfunction, and emerging lipidomic biomarkers that suggest causal relationships between specific lipid species, inflammatory mediators, and cardiovascular risk. Attention is also given to current strategies for the assessment and prevention of cardiovascular risk in IBD, emphasizing the importance of controlling disease activity, minimizing corticosteroid exposure, and aggressive treatment of modifiable cardiovascular risk factors. Traditional risk calculators may underestimate risk in this population, highlighting the need for tools that integrate inflammatory burden and imaging of subclinical atherosclerosis. Optimization of anti-inflammatory therapy along with individualized cardiovascular prevention strategies may improve long-term outcomes in patients with IBD.<\/jats:p>","DOI":"10.3389\/fendo.2026.1860937","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:29:05Z","timestamp":1781843345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue"],"prefix":"10.3389","volume":"17","author":[{"given":"Eva","family":"Karaskova","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Friedecky","sequence":"additional","affiliation":[{"name":"Laboratory for Inherited Metabolic Disorders, Department of Biochemistry, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kleparnik","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Palkovska","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radana","family":"Brumarova","sequence":"additional","affiliation":[{"name":"Laboratory for Inherited Metabolic Disorders, Department of Biochemistry, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Karasek","sequence":"additional","affiliation":[{"name":"3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s43657-024-00193-7","article-title":"Precision dietary intervention: Gut microbiome and meta-metabolome as functional readouts","volume":"5","author":"Luo","year":"2025","journal-title":"Phenomics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1696576","article-title":"The dietary phytochemicals carnosic acid and sulforaphane regulate inflammatory markers in ulcerative colitis patient-derived colonoids","volume":"16","author":"Rivera Rodr\u00edguez","year":"2025","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.106039","article-title":"Harnessing dental stem cell-derived synovial cells for IBD therapy: dual modulation of gut immunity and crypt repair","volume":"122","author":"Liu","year":"2025","journal-title":"EBioMedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310283","article-title":"Microbiota-induced obesity requires farnesoid X receptor","volume":"66","author":"Pars\u00e9us","year":"2017","journal-title":"Gut"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani","year":"2007","journal-title":"Diabetes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109400","article-title":"Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk","volume":"368","author":"Tang","year":"2013","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/metabo16030181","article-title":"Metabolic disorders and inflammatory bowel diseases: Unraveling shared pathways and clinical interactions","volume":"16","author":"Fousekis","year":"2026","journal-title":"Metabolites"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105981","article-title":"Significance of integrated clinical and proteomic characteristics analysis for pathogenesis and management of Crohn's disease with concomitant psoriasis","volume":"121","author":"Zhang","year":"2025","journal-title":"EBioMedicine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105987","article-title":"Identification of specific brain cell types associated with the interplay between inflammatory bowel diseases and neuropsychiatric disorders by cell-stratified Mendelian randomisation","volume":"122","author":"Zhou","year":"2025","journal-title":"EBioMedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.10.027","article-title":"Inflammatory bowel disease and atherosclerotic cardiovascular disease: JACC review topic of the week","volume":"76","author":"Cainzos-Achirica","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2025.102056","article-title":"Atherosclerotic cardiovascular disease and inflammatory bowel disease: epidemiology, pathogenesis and risk assessment","volume":"78","author":"Puca","year":"2025","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211032126","article-title":"Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management","volume":"14","author":"Sleutjes","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/joim.70035","article-title":"Association of histologic and clinical activity with major adverse cardiovascular events in patients with inflammatory bowel disease: A cohort study","volume":"298","author":"Sun","year":"2025","journal-title":"J Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0327734","article-title":"Strategies for assessing and preventing cardiovascular disease risk in inflammatory bowel disease patients: A meta-analysis and meta-regression and bibliometric review","volume":"20","author":"Liu","year":"2025","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11883-025-01329-4","article-title":"From gut inflammation to cardiovascular conflagration: Mapping IBD's cardiometabolic risks","volume":"27","author":"Noble","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2174971","article-title":"The oft-overlooked cardiovascular complications of inflammatory bowel disease","volume":"19","author":"Massironi","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2022.08.012","article-title":"Inflammatory bowel disease and cardiovascular diseases","volume":"135","author":"Chen","year":"2022","journal-title":"Am J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00300.2022","article-title":"Cardiovascular manifestations of inflammatory bowel diseases and the underlying pathogenic mechanisms","volume":"325","author":"Xiao","year":"2023","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03154-2","article-title":"Management of atherosclerotic cardiovascular risk in inflammatory bowel disease: Current perspectives","volume":"42","author":"Masson","year":"2025","journal-title":"Adv Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8624-5","article-title":"Unmet needs in the pathogenesis and treatment of cardiovascular comorbidities in chronic inflammatory diseases","volume":"55","author":"Panico","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2022.05.023","article-title":"Hearts on fire: The role of inflammation in the pathogenesis of atherosclerotic cardiovascular disease and how we can tend to the flames","volume":"38","author":"Boczar","year":"2022","journal-title":"Can J Cardiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2023.01.002","article-title":"Mechanistic insight: Linking cardiovascular complications of inflammatory bowel disease","volume":"34","author":"Kumarapperuma","year":"2024","journal-title":"Trends Cardiovasc Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2097274","article-title":"The immunological basis of inflammatory bowel disease","volume":"2016","author":"Silva","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/0003319720974552","article-title":"Atherosclerosis and inflammatory bowel disease-shared pathogenesis and implications for treatment","volume":"72","author":"Kamperidis","year":"2021","journal-title":"Angiology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cells14141124","article-title":"Cellular and Molecular Mechanisms Explaining the Link Between Inflammatory Bowel Disease and Heart Failure","volume":"14","author":"Shokravi","year":"2025","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvv145","article-title":"Pro-inflammatory TNF\u03b1 and IL-1\u03b2 differentially regulate adhesion molecules VCAM-1 and ICAM-1 in endothelial cells","volume":"107","author":"Kofler","year":"2015","journal-title":"Cardiovasc Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137154","article-title":"Effects of cytokines on Th1 and Th17 polarization and their role in vascular inflammation","volume":"22","author":"Ganjali","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020226","article-title":"Inflammatory Chemokines in Atherosclerosis","volume":"10","author":"Gencer","year":"2021","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.09.584","article-title":"Inflammatory bowel disease and atherosclerotic cardiovascular disease: JACC review topic of the week","volume":"76","author":"Wu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150202161500","article-title":"Cardiovascular complications in inflammatory bowel disease","volume":"16","author":"Schicho","year":"2022","journal-title":"Curr Drug Targets"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105775","article-title":"Long-term in vivo monitoring of transplanted mesenchymal stromal cells in colitis mice with magnetic particle imaging","volume":"116","author":"Shao","year":"2025","journal-title":"EBioMedicine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105440","article-title":"Development of a deep learning algorithm for Paneth cell density quantification for inflammatory bowel disease","volume":"110","author":"Kang","year":"2024","journal-title":"EBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41569-022-00737-2","article-title":"Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease","volume":"20","author":"Violi","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1143293","article-title":"Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the heart of the issue","volume":"10","author":"Gabbiadini","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00705","article-title":"Platelet toll-like receptors mediate thromboinflammatory responses in patients with essential thrombocythemia","volume":"11","author":"Mar\u00edn Oyarz\u00fan","year":"2020","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.thromres.2021.11.019","article-title":"Toll-like receptor 4 activation in platelets from myocardial infarction patients","volume":"209","author":"Barill\u00e0","year":"2022","journal-title":"Thromb Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-47","article-title":"Is atherosclerosis an autoimmune disease","volume":"12","author":"Matsuura","year":"2014","journal-title":"BMC Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/cvr\/cvn099","article-title":"Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans","volume":"79","author":"Nakashima","year":"2008","journal-title":"Cardiovasc Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.070513","article-title":"Heterogeneity of human macrophages in culture and in atherosclerotic plaques","volume":"172","author":"Waldo","year":"2008","journal-title":"Am J Pathol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.99.25.3218","article-title":"C(-260)-->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction","volume":"99","author":"Hubacek","year":"1999","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cells14100738","article-title":"Neutrophils at the crossroads of inflammatory bowel disease and atherosclerosis: A state-of-the-art review","volume":"14","author":"Genkel","year":"2025","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.5551\/jat.63887","article-title":"Distinct WBC trajectories are associated with the risks of incident CVD and all-cause mortality","volume":"30","author":"Yang","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.896645","article-title":"Neutrophil infiltration characterized by upregulation of S100A8, S100A9, S100A12 and CXCR2 is associated with the co-occurrence of Crohn's disease and peripheral artery disease","volume":"13","author":"Yao","year":"2022","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: An overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cells12232709","article-title":"NLRP3-induced NETosis: A potential therapeutic target for ischemic thrombotic diseases","volume":"12","author":"Kumar","year":"2023","journal-title":"Cells"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1161\/hq0102.101100","article-title":"Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs","volume":"22","author":"Little","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00123","article-title":"Serum biomarkers for inflammatory bowel disease","volume":"7","author":"Chen","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05050-8","article-title":"Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease","volume":"352","author":"Binion","year":"1998","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14361","article-title":"Vascular endothelial growth factor in inflammatory bowel disease: A systematic review and meta-analysis","volume":"55","author":"Zoroddu","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000214","article-title":"Overview of link between inflammatory bowel disease and cardiovascular disease","volume":"26","author":"Nevulis","year":"2018","journal-title":"Cardiol Rev"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i40.6757","article-title":"Venous and arterial thromboembolism in patients with inflammatory bowel diseases","volume":"27","author":"Stadnicki","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.9.993","article-title":"Inflammatory and thrombotic mechanisms in coronary atherosclerosis","volume":"89","author":"Tousoulis","year":"2003","journal-title":"Heart"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20896","article-title":"Inflammatory bowel disease: A paradigm for the link between coagulation and inflammation","volume":"15","author":"Yoshida","year":"2009","journal-title":"Inflammation Bowel Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3748\/wjg.v20.i1.53","article-title":"Inflammatory bowel disease: Epidemiology, pathology and risk factors for hypercoagulability","volume":"20","author":"Owczarek","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/BF02208650","article-title":"Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease","volume":"40","author":"Souto","year":"1995","journal-title":"Dig Dis Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.2.247","article-title":"Thromboembolism in inflammatory bowel disease: Role of platelets","volume":"34","author":"Webberley","year":"1993","journal-title":"Gut"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/nu9040382","article-title":"Associations between folate and vitamin B12 levels and inflammatory bowel disease: A meta-analysis","volume":"9","author":"Pan","year":"2017","journal-title":"Nutrients"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41469.x","article-title":"Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease","volume":"100","author":"Danese","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1015890","article-title":"Overrepresentation of Enterobacteriaceae and Escherichia coli is the major gut microbiome signature in Crohn's disease and ulcerative colitis; a comprehensive metagenomic analysis of IBDMDB datasets","volume":"12","author":"Khorsand","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.837509","article-title":"Role of butyrate, a gut microbiota derived metabolite, in cardiovascular diseases: A comprehensive narrative review","volume":"12","author":"Amiri","year":"2022","journal-title":"Front Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/ibd\/izz119","article-title":"Intestinal inflammation modulates the epithelial response to butyrate in patients with inflammatory bowel disease","volume":"26","author":"Ferrer-Pic\u00f3n","year":"2020","journal-title":"Inflammation Bowel Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304833","article-title":"A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis","volume":"63","author":"Machiels","year":"2014","journal-title":"Gut"},{"key":"B70","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/10815589251346966","article-title":"Bridging the gut and the heart-exploring pathophysiology, risk factors, and therapeutic implications of cardiovascular disease in inflammatory bowel disease","volume":"73","author":"Othon-Mart\u00ednez","year":"2025","journal-title":"J Investig Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1038\/s41598-018-22076-4","article-title":"Localization of lipopolysaccharide from Escherichia coli into human atherosclerotic plaque","volume":"8","author":"Carnevale","year":"2018","journal-title":"Sci Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20019","article-title":"Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease","volume":"13","author":"Pastor Rojo","year":"2007","journal-title":"Inflammation Bowel Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90496.2008","article-title":"A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis","volume":"296","author":"Ungaro","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.06.075","article-title":"Trimethylamine N-oxide prime NLRP3 inflammasome via inhibiting ATG16L1-induced autophagy in colonic epithelial cells","volume":"490","author":"Yue","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3797-3","article-title":"Trimethylamine-N-oxide: A novel biomarker for the identification of inflammatory bowel disease","volume":"60","author":"Wilson","year":"2015","journal-title":"Dig Dis Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.118.311023","article-title":"Gut microbiota-dependent trimethylamine N-oxide predicts risk of cardiovascular events in patients with stroke and is related to proinflammatory monocytes","volume":"38","author":"Haghikia","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060573","article-title":"Gut microbiota-derived trimethylamine N-oxide contributes to abdominal aortic aneurysm through inflammatory and apoptotic mechanisms","volume":"147","author":"Benson","year":"2023","journal-title":"Circulation"},{"key":"B78","article-title":"Association of TMAO levels with indicators of ulcerative colitis activity","volume":"16","author":"Laryushina","year":"2024","journal-title":"Caspian J Intern Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.03.008","article-title":"Microbially produced imidazole propionate is associated with heart failure and mortality","volume":"11","author":"Molinaro","year":"2023","journal-title":"JACC Heart Fail"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.124.322346","article-title":"Gut microbial metabolite imidazole propionate impairs endothelial cell function and promotes the development of atherosclerosis","volume":"45","author":"Nageswaran","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/nu14132664","article-title":"Bile acid-related regulation of mucosal inflammation and intestinal motility: From pathogenesis to therapeutic application in IBD and microscopic colitis","volume":"14","author":"Di Vincenzo","year":"2022","journal-title":"Nutrients"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2024.02.019","article-title":"Changes in bile acid subtypes and improvements in lipid metabolism and atherosclerotic cardiovascular disease risk: The Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost) trial","volume":"119","author":"Heianza","year":"2024","journal-title":"Am J Clin Nutr"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i24.107661","article-title":"Cardiometabolic diseases in patients with inflammatory bowel disease: An evidence-based review","volume":"31","author":"Dutt","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s43856-025-01123-y","article-title":"Visceral adipose tissue and hepatic fat as determinants of carotid atherosclerosis","volume":"5","author":"de Souza","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4","DOI":"10.14744\/nci.2017.74508","article-title":"Echocardiographic epicardial fat thickness measurement: A new screening test for subclinic atherosclerosis in patients with inflammatory bowel diseases","volume":"4","author":"Ozdil","year":"2017","journal-title":"North Clin Istanb"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/biom9120780","article-title":"Role of obesity, mesenteric adipose tissue, and adipokines in inflammatory bowel diseases","volume":"9","author":"Bilski","year":"2019","journal-title":"Biomolecules"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084226","article-title":"Role of adipose tissue in inflammatory bowel disease","volume":"22","author":"Karaskova","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000873","article-title":"Hypertrophic mesenteric adipose tissue may play a role in atherogenesis in inflammatory bowel diseases","volume":"22","author":"Theocharidou","year":"2016","journal-title":"Inflammation Bowel Dis"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/biom15081185","article-title":"Obesity-mediated inflammation and its influence on inflammatory bowel disease: Pathophysiology, clinical impact, and therapeutic implications","volume":"15","author":"Casas-Deza","year":"2025","journal-title":"Biomolecules"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.934854","article-title":"Circulating levels of WISP-1 (Wnt1-inducible signaling pathway protein 1) and other selected adipokines in children with inflammatory bowel disease","volume":"71","author":"Kar\u00e1skov\u00e1","year":"2022","journal-title":"Physiol Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1694061","article-title":"The molecular interplay among gut dysbiosis, adipose tissue, and metabolite-derived damage-associated molecular patterns in metainflammation and atherogenesis","volume":"16","author":"Gonz\u00e1lez-Hermosillo","year":"2025","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198905","article-title":"Creeping fat exhibits distinct inflammation-specific adipogenic preadipocytes in Crohn's disease","volume":"14","author":"Hwang","year":"2023","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad141","article-title":"Transcriptomic profiling and cellular composition of creeping fat in Crohn's disease","volume":"18","author":"Kim","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac266","article-title":"Single-cell expression atlas reveals cell heterogeneity in the creeping fat of Crohn's disease","volume":"29","author":"Shu","year":"2023","journal-title":"Inflammation Bowel Dis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12349","article-title":"Creeping fat formation and interaction with intestinal disease in Crohn's disease","volume":"10","author":"Yin","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.10.034","article-title":"Creeping fat-derived free fatty acids induce hyperplasia of intestinal muscularis propria muscle cells: A novel link between fat and intestinal stricture formation in Crohn's disease","volume":"168","author":"Liu","year":"2025","journal-title":"Gastroenterology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cell.2020.09.009","article-title":"Translocation of viable gut microbiota to mesenteric adipose drives formation of creeping fat in humans","volume":"183","author":"Ha","year":"2020","journal-title":"Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082448","article-title":"Microbial signature in adipose tissue of Crohn's disease patients","volume":"9","author":"Serena","year":"2020","journal-title":"J Clin Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"13513","DOI":"10.1038\/s41598-024-63893-0","article-title":"Elevated fecal calprotectin is associated with gut microbial dysbiosis, altered serum markers and clinical outcomes in older individuals","volume":"14","author":"Heinzel","year":"2024","journal-title":"Sci Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2410297","article-title":"C-reactive protein in atherosclerosis-more than a biomarker, but not just a culprit","volume":"24","author":"Kirkg\u00f6z","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.10.008","article-title":"Microbiota-induced alteration of kynurenine metabolism in macrophages drives formation of creeping fat in Crohn's disease","volume":"32","author":"Wu","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B102","doi-asserted-by":"crossref","DOI":"10.5772\/65491","article-title":"Interplay between hypoxia, inflammation and adipocyte remodeling in the metabolic syndrome","volume-title":"Hypoxia and Human Diseases","author":"Andrei","year":"2017"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1612676","article-title":"Exploring the molecular characteristics of inflammatory bowel disease from the perspective of hypoxia-related genes","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Pharmacol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123256","article-title":"The impact of obesity on inflammatory bowel disease","volume":"11","author":"Kaazan","year":"2023","journal-title":"Biomedicines"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.sjg_30_21","article-title":"Obesity in inflammatory bowel disease: a review of its role in the pathogenesis, natural history, and treatment of IBD","volume":"27","author":"Johnson","year":"2021","journal-title":"Saudi J Gastroenterol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf098","article-title":"Unravelling the relationship between obesity and inflammatory bowel disease","volume":"31","author":"Sun","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B107","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40259-022-00522-0","article-title":"Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases","volume":"36","author":"Bassi","year":"2022","journal-title":"BioDrugs"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2010.08.021","article-title":"Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease","volume":"4","author":"Sappati Biyyani","year":"2010","journal-title":"J Clin Lipidol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1198988","article-title":"Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis","volume":"10","author":"Chen","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3390\/nu14153040","article-title":"Dyslipidaemia is associated with severe disease activity and poor prognosis in ulcerative colitis: a retrospective cohort study in China","volume":"14","author":"Liu","year":"2022","journal-title":"Nutrients"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/s1568-9972(01)00018-0","article-title":"High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation","volume":"1","author":"Burger","year":"2002","journal-title":"Autoimmun Rev"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.10.072","article-title":"Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week","volume":"73","author":"Armitage","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2025.100836","article-title":"Targeting to high density lipoprotein cholesterol: new insights for inflammatory bowel disease treatment","volume":"66","author":"Wang","year":"2025","journal-title":"J Lipid Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"3","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac100","article-title":"Lipid changes after induction therapy in patients with inflammatory bowel disease: effect of different drug classes and inflammation","volume":"29","author":"Sleutjes","year":"2023","journal-title":"Inflammation Bowel Dis"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2023.2194631","article-title":"Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Shehab","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.02.017","article-title":"Statins and inflammatory bowel disease: where do we stand","volume":"75","author":"Peppas","year":"2020","journal-title":"Eur J Intern Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf077","article-title":"Statin use is associated with a less severe disease course in inflammatory bowel disease: a nationwide cohort study 2006-2020","volume":"31","author":"Khalili","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/joim.70034","article-title":"Statin use for primary prevention of cardiovascular disease reduces the risk of incident IBD: a population-based cohort study","volume":"298","author":"Faye","year":"2025","journal-title":"J Intern Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01252-1","article-title":"Lipid-lowering drugs and inflammatory bowel disease's risk: a drug-target Mendelian randomization study","volume":"16","author":"Zhao","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1160312","article-title":"Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study","volume":"14","author":"Tao","year":"2023","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14067","article-title":"Association between the use of lipid-lowering drugs and the risk of inflammatory bowel disease","volume":"53","author":"Liu","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2025.100871","article-title":"Lipid-lowering drug targets influence inflammatory bowel disease through gut microbiota and inflammatory cytokines","volume":"66","author":"Huang","year":"2025","journal-title":"J Lipid Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.31083\/RCM44003","article-title":"Lipoprotein(a) and high-risk coronary plaques: mechanisms, characteristics, and emerging therapeutic strategies","volume":"26","author":"Fang","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1038\/s41598-025-88375-9","article-title":"Mendelian randomization analysis does not support a causal influence between lipoprotein(A) and immune-mediated inflammatory diseases","volume":"15","author":"Ti","year":"2025","journal-title":"Sci Rep"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200112000-00004","article-title":"Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis","volume":"13","author":"Koutroubakis","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2025.107303","article-title":"Prevalence of elevated lipoprotein(a) in individuals with inflammatory bowel disease: potential implications for cardiovascular risk","volume":"166","author":"Masson","year":"2026","journal-title":"Med Clin (Barc)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20200930-00847","article-title":"Correlation of serum lipid profile and disease activity in patients with inflammatory bowel disease","volume":"60","author":"Wang","year":"2021","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167806","article-title":"Lipidomics and cardiovascular disease","volume":"1871","author":"Surendran","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.05.041","article-title":"Revealing the potential of lipidomics: improving cardiovascular risk assessment","volume":"84","author":"Song","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1104901","article-title":"The human plasma lipidome","volume":"365","author":"Quehenberger","year":"2011","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"B134","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12876-025-03858-3","article-title":"Unveiling the influence of lipidomes on inflammatory bowel disease: a bidirectional mendelian randomization study","volume":"25","author":"Lei","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/fsn3.70916","article-title":"Causal association of plasma lipidome with inflammatory bowel diseases and mediating role of circulating inflammatory proteins: a mendelian randomization study","volume":"13","author":"Yin","year":"2025","journal-title":"Food Sci Nutr"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad298","article-title":"Unique metabolomic and lipidomic profile in serum from patients with Crohn's disease and ulcerative colitis compared with healthy control individuals","volume":"30","author":"Tews","year":"2024","journal-title":"Inflammation Bowel Dis"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/biom10071083","article-title":"Sphingolipid analysis indicate lactosylceramide as a potential biomarker of inflammatory bowel disease in children","volume":"10","author":"Filimoniuk","year":"2020","journal-title":"Biomolecules"},{"key":"B138","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1038\/s41467-024-48763-7","article-title":"Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease","volume":"15","author":"Salihovic","year":"2024","journal-title":"Nat Commun"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz098","article-title":"Lipidomics in ulcerative colitis reveal alteration in mucosal lipid composition associated with the disease state","volume":"25","author":"Diab","year":"2019","journal-title":"Inflammation Bowel Dis"},{"key":"B140","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12876-025-03944-6","article-title":"Marked mucosal lipid shifts in treatment refractory inflammatory bowel disease: a lipidomic study","volume":"25","author":"Moe","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14155485","article-title":"Decline in serum lysophosphatidylcholine species in patients with severe inflammatory bowel disease","volume":"14","author":"Tews","year":"2025","journal-title":"J Clin Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1600-0897.2011.01089.x","article-title":"Short-chain fatty acids induce pro-inflammatory cytokine production alone and in combination with toll-like receptor ligands","volume":"67","author":"Mirmonsef","year":"2012","journal-title":"Am J Reprod Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01369-21","article-title":"The short-chain fatty acids propionate and butyrate augment adherent-invasive Escherichia coli virulence but repress inflammation in a human intestinal enteroid model of infection","volume":"9","author":"Pace","year":"2021","journal-title":"Microbiol Spectr"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1322269111","article-title":"The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition","volume":"111","author":"Chang","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B145","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mi.2014.44","article-title":"Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway","volume":"8","author":"Park","year":"2015","journal-title":"Mucosal Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00587-20","article-title":"Microbiota-derived short-chain fatty acids promote LAMTOR2-mediated immune responses in macrophages","volume":"5","author":"Wu","year":"2020","journal-title":"mSystems"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1017\/gmb.2022.1","article-title":"Higher total faecal short-chain fatty acid concentrations correlate with increasing proportions of butyrate and decreasing proportions of branched-chain fatty acids across multiple human studies","volume":"3","author":"LaBouyer","year":"2022","journal-title":"Gut Microbiome (Camb)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0168","article-title":"Butyrate producing bacteria and insulin homeostasis: the microbiome and insulin longitudinal evaluation study (MILES)","volume":"71","author":"Cui","year":"2022","journal-title":"Diabetes"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282685","article-title":"Butyrate suppresses atherosclerotic inflammation by regulating macrophages and polarization via GPR43\/ HDAC-miRNAs axis in ApoE-\/- mice","volume":"18","author":"Ma","year":"2023","journal-title":"PloS One"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4646245","article-title":"Sodium butyrate attenuated diabetes induced intestinal inflammation by modulating gut microbiota","volume":"2022","author":"Liu","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa258","article-title":"Cardiovascular risk assessment and impact of medications on cardiovascular disease in inflammatory bowel disease","volume":"27","author":"Sinh","year":"2021","journal-title":"Inflammation Bowel Dis"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy164","article-title":"Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals","volume":"13","author":"Aarestrup","year":"2019","journal-title":"J Crohns Colitis"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2025.1011","article-title":"Epidemiology of metabolic syndrome in patients with inflammatory bowel disease: a population-level cohort study from the United States","volume":"38","author":"Desai","year":"2025","journal-title":"Ann Gastroenterol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/208919","article-title":"Association between metabolic syndrome and inflammatory bowel disease: a bidirectional two-sample mendelian randomized study","volume":"22","author":"Wang","year":"2026","journal-title":"Arch Med Sci"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184102","article-title":"QRISK3 performance in the assessment of cardiovascular risk in patients with inflammatory bowel disease","volume":"10","author":"Carrillo-Palau","year":"2021","journal-title":"J Clin Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081671","article-title":"Carotid plaque assessment reclassifies patients with inflammatory bowel disease into very-high cardiovascular risk","volume":"10","author":"Hern\u00e1ndez-Camba","year":"2021","journal-title":"J Clin Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.08.011","article-title":"Coronary artery calcium scoring for cardiovascular risk assessment in patients with inflammatory bowel disease","volume":"266","author":"Naami","year":"2023","journal-title":"Am Heart J"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1177\/0003319716652031","article-title":"Subclinical atherosclerosis in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"68","author":"Wu","year":"2017","journal-title":"Angiology"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa235","article-title":"Association between statin use and inflammatory bowel diseases: results from a Swedish, nationwide, population-based case-control study","volume":"15","author":"Lochhead","year":"2021","journal-title":"J Crohns Colitis"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/diseases11010006","article-title":"Are drugs associated with microscopic colitis? A systematic review and meta-analysis","volume":"11","author":"Tarar","year":"2022","journal-title":"Diseases"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-25-00268","article-title":"Medications and risk for microscopic colitis: a nationwide study of older adults in Sweden","volume":"178","author":"Khalili","year":"2025","journal-title":"Ann Intern Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjag034","article-title":"Statin use is associated with lower rates of stricture development in patients with Crohn's disease: a propensity score-matched study of two nationwide population databases","volume":"20","author":"Dimopoulos-Verma","year":"2026","journal-title":"J Crohns Colitis"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1693342","article-title":"Association between statin use and the risk of colorectal cancer in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"16","author":"Ding","year":"2026","journal-title":"Front Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073071","article-title":"Chronic inflammatory diseases and cardiovascular risk: current insights and future strategies for optimal management","volume":"26","author":"Cacciatore","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2654-7","article-title":"Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial","volume":"33","author":"Fatemi","year":"2014","journal-title":"Clin Rheumatol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2023.06.030","article-title":"Optimal prescribing of statins to reduce cardiovascular disease","volume":"136","author":"Schade","year":"2023","journal-title":"Am J Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097193","article-title":"Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease","volume":"9","author":"Arab","year":"2014","journal-title":"PloS One"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001016","article-title":"\u03b2-blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study","volume":"30","author":"Willemze","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308533","article-title":"Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: a population-based study","volume":"19","author":"Karacabeyli","year":"2024","journal-title":"PloS One"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000847","article-title":"GLP-1 induces barrier protective expression in Brunner's glands and regulates colonic inflammation","volume":"22","author":"Bang-Berthelsen","year":"2016","journal-title":"Inflammation Bowel Dis"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B174","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/ibd\/izae090","article-title":"Effectiveness and safety of semaglutide for weight loss in patients with inflammatory bowel disease and obesity","volume":"31","author":"Desai","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf078","article-title":"Association between inflammatory bowel disease, current therapies, and cardiovascular events: a review and meta-analysis of data from 2.2 million individuals","volume":"19","author":"Thomas","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186476","article-title":"The cardiovascular effects of inflammatory bowel disease therapy with biologics and small molecules: a comprehensive review","volume":"14","author":"Mastoridou","year":"2025","journal-title":"J Clin Med"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2024.03.010","article-title":"Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus","volume":"56","author":"Olivera","year":"2024","journal-title":"Dig Liver Dis"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17509","article-title":"Review article: risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs","volume":"57","author":"Olivera","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"B179","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis","volume":"22","author":"Mattay","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1860937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:29:08Z","timestamp":1781843348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1860937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":179,"alternative-id":["10.3389\/fendo.2026.1860937"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1860937","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1860937"}}